All In Biotech

Investigational drug · Phase 2

TL117

Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Head and Neck Squamous Cell Carcinoma.

Phase 2

Last checked: Nov 19, 2026Latest source record: Dec 9, 2024 (newest trial update)Source: ClinicalTrials.govMethods & limitations

Highest phase

Phase 2

Industry-sponsored trials

Phase 2 and 3 trials

1

1 still active

All registered trials

1

Any phase or sponsor naming "TL117"

First trial start

2021

May 26, 2021

Sponsors

Lead sponsors of its Phase 2 and 3 trials.

All registered trials by phase

Every ClinicalTrials.gov drug study naming "TL117", any sponsor or status.

Conditions studied

As listed on its trial records.

  • Head and Neck Squamous Cell Carcinoma

Approved drugs for the same conditions: Head and neck cancer · Oncology

Largest trials

Live from ClinicalTrials.gov: studies naming "TL117" as an intervention, largest first.

All trials

Newest research

PubMed records naming it or its code names, newest first.

All 2 on PubMed

Also in development for Head and Neck Squamous Cell Carcinoma

  • BMS-986507BL-B01D1, Iza-brenPhase 351 trials

    Sichuan Baili Pharmaceutical Co., Ltd. · Non-small Cell Lung Cancer, Solid Tumor, Urothelial Carcinoma

  • HS-20093Ris-Rez, Risvutatug rezetecanPhase 316 trials

    Hansoh BioMedical R&D Company · Neoplasms, Lung, Sarcoma, Osteosarcoma

  • Telisotuzumab AdizutecanABBV-400Phase 316 trials

    AbbVie · c-MET, Non-Squamous Non-Small Cell Lung Cancer, Metastatic Colorectal Cancer

  • SG001enlonstobart, Enlonstobart will be administrated on a 14-day cyclePhase 315 trials

    CSPC Megalith Biopharmaceutical Co.,Ltd. · HER2-positive Gastric Cancer, Esophageal Squamous Cell Carcinoma, Head and Neck Squamous Cell Carcinoma

  • SYS6010Phase 315 trials

    CSPC Megalith Biopharmaceutical Co.,Ltd. · Non-Small Cell Lung Cancer, Esophageal Squamous Cell Carcinoma, Head and Neck Squamous Cell Carcinoma

  • AK117Phase 314 trials

    Akeso · Advanced Malignant Tumors, ACUTE MYELOID LEUKEMIA; AML, Higher-risk Myelodysplastic Syndromes

  • FianlimabREGN3767Phase 311 trials

    Regeneron · Melanoma, Non-small Cell Lung Cancer, Hepatocellular Carcinoma

  • ZanzalintinibXL092Phase 311 trials

    Exelixis · Colorectal Cancer, Renal Cell Carcinoma, Head and Neck Squamous Cell Carcinoma

Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.